Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Eur J Haematol. 2019 Mar;102(3):235-240. doi: 10.1111/ejh.13198. Epub 2019 Jan 1.

Abstract

Objectives: The study investigates the hypothesis that inflammation in myelofibrosis (MF) like in myeloma and lymphoma, may disturb iron distribution and contribute to anaemia.

Methods: A cross-sectional study of 80 MF and 23 ET patients was performed.

Results: About 35% of anaemic MF patients had functional iron deficiency (FID) with transferrin saturation <20 and normal or elevated S-ferritin (<500 µg/L). In ET, FID was rare. In MF patients with FID, 70.6% were anaemic, vs 29.4% in patients without FID (P = 0.03). Hepcidin was significantly higher in MF patients with anaemia, including transfusion-dependent patients, 50.6 vs 24.4 µg/L (P = 0.01). There was a significant negative correlation between Hb and inflammatory markers in all MF patients: IL-2, IL-6 and TNF-α, (P < 0.01-0.03), LD (P = 0.004) and hepcidin (P = 0.03). These correlations were also seen in the subgroup of anaemic MF patients (Table ). Tsat correlated negatively with CRP (P < 0.001). Symptom burden was heavier in MF patients with FID, and MPN-SAF quality of life scores correlated with IL-6 and CRP.

Conclusions: The inflammatory state of MF disturbs iron turnover, FID is common and contributes to anaemia development and impairment of QoL. Anaemic MF patients should be screened for FID.

Keywords: Myelofibrosis; anaemia of inflammation; cytokines; functional iron deficiency.

MeSH terms

  • Anemia, Iron-Deficiency / diagnosis
  • Anemia, Iron-Deficiency / epidemiology*
  • Anemia, Iron-Deficiency / etiology*
  • Biomarkers
  • Blood Chemical Analysis
  • Bone Marrow / pathology
  • Cross-Sectional Studies
  • Cytokines / blood
  • Cytokines / metabolism
  • Ferritins / blood
  • Humans
  • Inflammation / complications*
  • Inflammation / pathology
  • Inflammation Mediators
  • Iron / blood
  • Primary Myelofibrosis / complications*
  • Primary Myelofibrosis / epidemiology*
  • Primary Myelofibrosis / pathology
  • Quality of Life*

Substances

  • Biomarkers
  • Cytokines
  • Inflammation Mediators
  • Ferritins
  • Iron